Ameriprise’s KalVista Pharmaceuticals KALV Stock Holding History

Ameriprise’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.63M	Buy	229,984 +195,055	+558%	+$3.14M	﹤0.01%	2483
2025 Q4	$564K	Sell	34,929 -520	-1%	-$6.89K	﹤0.01%	3578
2025 Q3	$432K	Sell	35,449 -909,676	-96%	-$12.6M	﹤0.01%	3678
2025 Q2	$10.7M	Buy	945,125 +905,053	+2,259%	+$11.1M	﹤0.01%	1767
2025 Q1	$462K	Sell	40,072 -13,310	-25%	-$136K	﹤0.01%	3520
2024 Q4	$452K	Buy	+53,382	New	+$553K	﹤0.01%	3559
2023 Q2	–	Sell	-13,131	Closed	-$103K	–	3957
2023 Q1	$103K	Buy	+13,131	New	+$98K	﹤0.01%	3825

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise's KALV Position: Q1 2026 in Review

Ameriprise increased its KalVista Pharmaceuticals (KALV) stake by 558% in Q1 2026, buying an estimated $3.14M and bringing the position to 229,984 shares worth $4.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2483.

Ameriprise first reported a position in KALV in Q1 2023 and has held it in 7 quarters since. The position peaked at $10.7M in Q2 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Ameriprise held 229,984 shares of KalVista Pharmaceuticals worth $4.63M as of Q1 2026.
Ameriprise bought 195,055 KalVista Pharmaceuticals shares in Q1 2026, an estimated $3.14M.
KalVista Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2483 holding.
Ameriprise first reported a position in KalVista Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
Ameriprise's KalVista Pharmaceuticals position peaked at $10.7M in Q2 2025.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.